Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Validation of a transcriptome-based assay for classifying cancers of unknown primary origin

Jackson Michuda, Alessandra Breschi, Joshuah Kapilivsky, Kabir Manghnani, Calvin McCarter, Adam J Hockenberry, Brittany Mineo, Catherine Igartua, Joel T Dudley, Martin C Stumpe, Nike Beaubier, Maryam Shirazi, Ryan Jones, Elizabeth Morency, Kim Blackwell, Justin Guinney, Kyle A Beauchamp, Timothy Taxter
doi: https://doi.org/10.1101/2022.05.06.22274683
Jackson Michuda
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandra Breschi
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshuah Kapilivsky
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kabir Manghnani
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Calvin McCarter
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam J Hockenberry
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brittany Mineo
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Igartua
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel T Dudley
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin C Stumpe
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nike Beaubier
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maryam Shirazi
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan Jones
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Morency
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Blackwell
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin Guinney
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyle A Beauchamp
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kyle.beauchamp{at}tempus.com tim{at}tempus.com
Timothy Taxter
Tempus Labs, Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kyle.beauchamp{at}tempus.com tim{at}tempus.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Cancers assume a variety of distinct histologies and may originate from a myriad of sites including solid organs, hematopoietic cells, and connective tissue. Clinical decision making based on consensus guidelines such as NCCN is often predicated on a specific histologic and anatomic diagnosis, supported by clinical features and pathologist interpretation of morphology and immunohistochemical (IHC) staining patterns. However, in patients with nonspecific morphologic and IHC findings—in addition to ambiguous clinical presentations such as recurrence versus new primary—a definitive diagnosis may not be possible, resulting in the patient being categorized as having a cancer of unknown primary (CUP). Therapeutic options and clinical outcomes are poor for CUP patients, with a median survival of 8-11 months. Here we describe and validate the Tempus Tumor Origin (Tempus TO) assay, an RNA-seq-based machine learning classifier capable of discriminating between 68 clinically relevant cancer subtypes. We show that the Tempus TO model is 91% accurate when assessed on retrospectively and prospectively held out cohorts of containing 9,210 samples with known diagnoses. When evaluated on a cohort of CUPs, the model recapitulated established associations between genomic alterations and cancer subtype. Combining diagnostic prediction tests (e.g., Tempus TO) with sequencing-based variant reporting (e.g., Tempus xT) may expand therapeutic options for patients with cancers of unknown primary or uncertain histology.

Competing Interest Statement

All authors are employees, former employees, and/or hold restricted stock units of Tempus Labs, Inc.

Funding Statement

All authors are current or former employees of Tempus Labs, who provided funding for this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All analyses were performed using de-identified data; IRB exemption Pro00042950 was obtained from Advarra on April 15, 2020.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • <jack.michuda{at}tempus.com>

  • <alessandra.breschi{at}tempus.com>

  • <joshuah.kapilivsky{at}tempus.com>

  • <kabir.manghnani{at}tempus.com>

  • <calvin.mccarter{at}tempus.com>

  • <adam.hockenberry{at}tempus.com>

  • <brittany.mineo{at}tempus.com>

  • <katie.igartua{at}tempus.com>

  • <joel.dudley{at}tempus.com>

  • <martin.stumpe{at}tempus.com>

  • <nike.beaubier{at}tempus.com>

  • <maryam.shirazi{at}tempus.com>

  • <ryan.jones{at}tempus.com>

  • <elizabeth.morency{at}tempus.com>

  • <kim.blackwell{at}tempus.com>

  • <justin.guinney{at}tempus.com>

  • Disclosure: All authors are employees, former employees, and/or hold restricted stock units of Tempus Labs, Inc.

Data Availability

Raw data for this study were generated at Tempus Labs. Derived data supporting the findings of this study are available within the paper and its Supplementary Figures/Tables or available from the authors upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted May 09, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Validation of a transcriptome-based assay for classifying cancers of unknown primary origin
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Validation of a transcriptome-based assay for classifying cancers of unknown primary origin
Jackson Michuda, Alessandra Breschi, Joshuah Kapilivsky, Kabir Manghnani, Calvin McCarter, Adam J Hockenberry, Brittany Mineo, Catherine Igartua, Joel T Dudley, Martin C Stumpe, Nike Beaubier, Maryam Shirazi, Ryan Jones, Elizabeth Morency, Kim Blackwell, Justin Guinney, Kyle A Beauchamp, Timothy Taxter
medRxiv 2022.05.06.22274683; doi: https://doi.org/10.1101/2022.05.06.22274683
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Validation of a transcriptome-based assay for classifying cancers of unknown primary origin
Jackson Michuda, Alessandra Breschi, Joshuah Kapilivsky, Kabir Manghnani, Calvin McCarter, Adam J Hockenberry, Brittany Mineo, Catherine Igartua, Joel T Dudley, Martin C Stumpe, Nike Beaubier, Maryam Shirazi, Ryan Jones, Elizabeth Morency, Kim Blackwell, Justin Guinney, Kyle A Beauchamp, Timothy Taxter
medRxiv 2022.05.06.22274683; doi: https://doi.org/10.1101/2022.05.06.22274683

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (432)
  • Allergy and Immunology (758)
  • Anesthesia (221)
  • Cardiovascular Medicine (3306)
  • Dentistry and Oral Medicine (365)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1174)
  • Epidemiology (13391)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5165)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3280)
  • Health Policy (1144)
  • Health Systems and Quality Improvement (1196)
  • Hematology (432)
  • HIV/AIDS (1021)
  • Infectious Diseases (except HIV/AIDS) (14647)
  • Intensive Care and Critical Care Medicine (914)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (525)
  • Neurology (4939)
  • Nursing (262)
  • Nutrition (733)
  • Obstetrics and Gynecology (886)
  • Occupational and Environmental Health (796)
  • Oncology (2526)
  • Ophthalmology (729)
  • Orthopedics (283)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (545)
  • Pediatrics (1303)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4221)
  • Public and Global Health (7520)
  • Radiology and Imaging (1709)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (981)
  • Rheumatology (480)
  • Sexual and Reproductive Health (499)
  • Sports Medicine (425)
  • Surgery (550)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (206)